Company intelligence / Profile preview
Organovo
San Diego, California, United Statesorganovo.com ↗
- Ownership
- Public · ONVO
- Development stage
- Other
01
Overview
The company’s lead program, FXR314, demonstrated positive Phase 2 results in MASH with significant reduction in liver fat content and strong safety/tolerability. Additional data presented show improved epithelial barrier function and fibrosis reduction in IBD models. The company also provides advanced preclinical tissue platforms to partners.
- Therapeutic areas
- GastroenterologyRare DiseasesMetabolic Disorders
- Modalities
- Small molecules (e.g., FXR agonists)3D bioprinted human tissues for drug discovery and disease modeling
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
L’Oreal (for skin tissue testing/cosmetic safety applications)Eli Lilly (purchased the FXR program in February 2025)
Beyond the preview
Go deeper on Organovo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Organovo.